Asset Details
Do you wish to reserve the book?
Identification of low-molecular compounds that inhibit envelope formation of hepatitis B virus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification of low-molecular compounds that inhibit envelope formation of hepatitis B virus
Do you wish to request the book?
Identification of low-molecular compounds that inhibit envelope formation of hepatitis B virus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Identification of low-molecular compounds that inhibit envelope formation of hepatitis B virus
2025
Overview
Agents with novel mechanisms are clinically needed for the functional cure of chronic hepatitis B virus (HBV) infection. This study aimed to identify compounds that inhibit an interaction between large hepatitis B surface (LHBs) and hepatitis B core (HBc) proteins, which are considered to be important for HBV envelope formation. Using a high-throughput screening method to evaluate the protein-protein interaction in HepG2 cells by the NanoBRET system, 3,200 compounds from our library were tested. Then, the inhibitory effects of the hit compounds on HBV particles with the envelope were evaluated in HBV-expressing HepG2.2.15.7 cells. 40 hit compounds were found to inhibit the interaction between LHBs and HBc, of which 10 compounds inhibited HBV particles. The top 5 compounds with the least variation were considered as candidates. These compounds showed little effects on HBV proteins and RNAs, whereas a hit compound 16, which showed the lowest IC50 (0.9 µM), decreased precore mRNA significantly. When the culture supernatant from cells with hit compound 16 was subjected to sucrose density gradient centrifugation, HBV particles with the envelope were found to be reduced. In conclusion, we identified compounds that might inhibit the envelope formation of HBV through disturbing the interaction between LHBs and HBc.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Antiviral Agents - pharmacology
/ Envelope
/ Enzymes
/ Hepatitis B virus - chemistry
/ Hepatitis B virus - drug effects
/ Hepatitis B virus - physiology
/ Hepatitis B, Chronic - drug therapy
/ High-Throughput Screening Assays
/ Humanities and Social Sciences
/ Humans
/ mRNA
/ NanoBRET
/ Peptides
/ Proteins
/ Ratios
/ Science
